Mammoth Biosciences CRISPR systems technology will be used by Vertex Pharmaceuticals to develop in vivo gene-editing therapies for two undisclosed genetic diseases, in a deal that has the potential to generate as much as $695 million for Mammoth, the two companies announced today.
We are focused on developing in vivo gene-editing therapies in two indications for specific serious and/or life-threatening diseases with the Vertex team,Peter Nell, Mammoths Chief Business Officer and Head of Therapeutics Strategy, told GEN.
Mammoth and Vertex did say, however, that they will apply Mammoths CRISPR platform consisting of a proprietary toolbox of novel Cas enzymeswhat the company calls the largest toolbox of CRISPR proteins on earth.
These include Cas12, which targets double-stranded DNA; Cas13, which targets and recognizes single-stranded RNA; Cas14, which targets single-stranded DNA; and Cas, which is encoded exclusively in the genomes of huge bacteriophages.
Mammoth has exclusively licensed foundational IP around novel CRISPR Cas12, Cas13, Cas14, and Cas systems from the University of California, Berkeley, where, they were discovered in the lab of Nobel laureate and Berkeley-based researcher Jennifer Doudna, Ph.D.
Doudna is a co-founder of Mammoth Biosciences along with CEO Trevor Martin, Ph.D.; Janice Chen, Ph.D., the companys CTO; Lucas Harrington, Mammoths CSO; and Ashley Tehranchi, Ph.D., who served as CTO until May 2019.
Cas14 and Cas are the smallest known CRISPR systems. Their sizes530 amino acids for Cas14a and 757 amino acids for Cas-2are less than half those of commonly used variants of Cas9 [1368 amino acids for SpCas9] and Cas12 [1,300 amino acids for FnCas12], offering numerous potential advantages for the therapies Mammoth plans to develop, Martintold GEN Edge last month, after the company announced the completion of $195 million in new financing completed over the past year.
The additional financingconsisting of $150 million in Series D financing and a $45-million Series C round whose investors included Amazonbrought Mammoths total capital raised from investors to more than $255 million., propelling the company to a unicorn valuation of more than $1 billion.
In addition, Mammoth said, it is building out its IP portfolio by discovering novel CRISPR systems within and beyond the foundational work. The company has yet to disclose those systems or other Cas enzymes under development.
The combination of Mammoths unique technology with Vertexs unmatched experience in serious disease research and development will only accelerate programs with the goal of reaching patients with high unmet medical need, Nell added. We believe our novel ultra-small CRISPR systems have the potential to be game-changers when it comes to systemic and targeted delivery of in vivo gene-editing therapies.
CRISPR-edited therapies have been an area of focus for Vertex. Late last year, the company and CRISPR Therapeuticsreported positive data from a pair of Phase I/II trialsfor their CRISPR-Cas9 gene-edited therapy CTX001 showing consistent and sustained positive response in 10 patients treated for a pair of blood disorders, sickle cell disease (SCD) and beta thalassemia.
The companies in April amended their collaboration agreement to give Vertex leadership in global development, manufacturing, and commercialization of CTX001 with support from CRISPR Therapeutics, in return for CRISPR receiving a $900 million upfront payment and a potential additional $200 million milestone payment upon CTX001 regulatory approval. Two months later, during the Joint European Hematology Association-American Society of Hematology (EHA-ASH) Symposium, researchers presented additional clinical data showing CTX001 to have delivered a consistent and sustained response to treatment in 22 patients in two ongoing Phase I/II trials.
We see tremendous potential for CTX001, Stuart A. Arbuckle, Vertexs executive vice president and chief commercial and operations officer, told analysts July 29 on the companys quarterly earnings call following release of second-quarter results. He cited an estimate of more than 150,000 patients in the United States and Europe, who have beta thalassemia, or sickle cell disease, approximately 32,000 of whom have severe disease; plus another 25,000 severe sickle cell disease patients, the vast majority of which were in the United States.
We believe that a gene-editing approach which holds the potential for a one-time curative treatment will be highly valued by patients, physicians, and payers, Arbuckle said. Consistent with our own internal market research, published physician surveys in the United States consistently indicate that they expect a quarter to a third of their sickle cell disease patients would be good candidates for a one-time curative approach using the current conditioning regimen, which is in line with the estimates of the numbers of severe patients.
With gentler conditioning regimens in the future, Arbuckle added, we expect CTX001 to be an attractive option for a much larger proportion of the 150,000 beta thalassemia and sickle cell disease patients.
To launch its collaboration with Mammoth, Vertex has agreed to pay the Brisbane, CA,-based company $41 million upfront, including an investment in the form of a convertible note, and up to $650 million in potential future payments tied to achieving research, development, and commercial milestones across two potential programs.
Mammoth is also eligible for tiered royalties from Boston-based Vertex on future net sales on any products that may result from the collaboration, the first one announced by Mammoth for the development of gene-edited therapies.
Vertex and Mammoth share the same commitment to developing therapies that have the potential to be transformative for people with serious diseases, stated David Altshuler, MD, PhD, Vertexs CSO. We look forward to expanding our cell and genetic therapies capabilities with the addition of Mammoths ultra-small CRISPR systems for in vivo genome editing, which will provide us with another set of tools to tackle many of the diseases were interested in.
Mammoth is also developing CRISPR-based diagnostics, having applied Cas12 in its COVID-19diagnostic effort which culminated in the SARS-CoV-2 RNA DETECTR Assay, a COVID-19 diagnostic for whichUCSF Health Clinical Laboratorieswasgranted an FDA Emergency Use Authorization (EUA)in August 2020.
The 45-minute test is designed to detect nucleic acid from SARS-CoV-2 in upper respiratory specimens. The test extracts, isolates, and purifies SARS-CoV-2 nucleic acid for simultaneous reverse transcription into cDNA, followed by amplification using loop-mediated amplification (RT-LAMP).
The SARS-CoV-2 RNA DETECTR Assay was co-developed by Mammoth through itspartnership with UCSF professor Charles Chiu, MD, PhD, who is also director of the UCSF-Abbott Viral Diagnostics and Discovery Center, and a member of the companys Scientific Advisory Board. Mammothin 2019exclusively licensed two U.S. patentsgranted to the regents of the University of California that cover CRISPR collateral cleavage diagnostic systems.
In July 2020, Mammoth won funding for its development of a scalable COVID-19 test, when the company wasawarded $23.1 millionof $248.7 million in contracts to the first seven lab-based and point-of-care tests diagnostics developersfunded through the NIHs Rapid Acceleration of Diagnostics (RADx) initiative. The testing system can be adapted to detect for other viruses, though Mammoth has not made public which ones.
Two months earlier in May 2020, Mammoth launched a collaboration with GlaxoSmithKlines GSK Consumer Healthcare to develop a handheld test designed to apply the DETECTR platform at point of need. Mammoth has disclosed few details since the initial announcement, with Martin saying last month: I cant say too much about it, but definitely weve made huge strides.
Read the original:
Vertex Taps Mammoth's CRISPR Tech in Gene Therapy Deal Worth up to $695M - Clinical OMICs News
- New gene therapy for sickle cell disease has been a long time coming, but is it a complete game-changer? - UCLA Health Connect - December 29th, 2023
- Sickle Cell Gene Therapy Reimbursement: Will Experience Matter? And Which Kind? - Pink Sheet - December 29th, 2023
- Cell and gene therapy will be top industry trend for pharma in 2024 - The Financial Express - December 29th, 2023
- Excision Bio Seeks to Suppress HIV Replication With CRISPR Gene Therapy - AJMC.com Managed Markets Network - December 29th, 2023
- Global Cell and Gene Therapy Manufacturing Industry is projected to surpass a valuation of US$ 240 B - PharmiWeb.com - December 29th, 2023
- Penn's gene therapy layoffs are the latest in biotech belt-tightening in Philly and beyond - The Philadelphia Inquirer - December 29th, 2023
- Adeno-associated Virus Gene Therapy Market is Projected to Grow at a CAGR of 43.4% from 2023-2033 - EIN News - December 29th, 2023
- How Does Gene Therapy Work? Types, Uses, Safety - Healthline - May 9th, 2023
- Gene therapy: Comprehensive overview and therapeutic applications - April 7th, 2023
- Thanks to collaboration between Stand Up Therapeutics and VectorBuilder, a paraplegic patient will get gene therapy for the first time - Business... - January 21st, 2023
- Gene editing | Definition, History, & CRISPR-Cas9 | Britannica - January 4th, 2023
- A short history of gene therapy - Boston Children's Answers - December 27th, 2022
- Gene Therapy Analytical Development Summit 2022 | Home - December 27th, 2022
- $3.5-Million Hemophilia Gene Therapy Is World's Most Expensive Drug - Scientific American - December 10th, 2022
- CAR T Global Consultant Inc. Announce their Collaboration with Titronbio - a company founded in Shanghai China by a renowned leader in the field of... - December 10th, 2022
- Cell and Gene Therapy Manufacturing Services Market Size In 2023 | Financial Performance, In-Depth Insight of Trends, Key Players (Thermo Fisher... - December 10th, 2022
- How Gene Therapy Can Cure or Treat Diseases | FDA - December 2nd, 2022
- FDA Approves First Gene Therapy to Treat Adults with Hemophilia B - FDA.gov - November 24th, 2022
- Fact Check-mRNA vaccines are distinct from gene therapy ... - Reuters - October 29th, 2022
- Gene therapy: The Potential for Treating Type 1 Diabetes - Healthline - October 13th, 2022
- The promised land of gene therapy: Commercialization of novel gene-editing technology in beta-thalassemia - PMLiVE - October 13th, 2022
- Gene Therapy Hits Its Stride in the Clinic - Genetic Engineering & Biotechnology News - October 13th, 2022
- FDA Expands Oversight of Cell and Gene Therapies - Pharmaceutical Technology Magazine - October 13th, 2022
- Rocket Pharmaceuticals Announces Presentations Highlighting Lentiviral Gene Therapies at the 29th Annual Congress of the European Society of Gene... - October 13th, 2022
- Health Alert for Parents: How one boy is thriving following treatment with a gene therapy after receiving an early diagnosis - PR Newswire - October 13th, 2022
- M6P Therapeutics Presents Novel AAV Gene Therapy Approach for the Treatment of Gaucher Disease at the ESGCT 29th Annual Congress - Business Wire - October 13th, 2022
- Two Cell and Gene Therapies Manufactured at Lonza Houston Reach FDA Approval - Contract Pharma - October 13th, 2022
- Ascidian starts up with $50M and a twist on RNA editing - BioPharma Dive - October 13th, 2022
- Viral Vector Manufacturing, Non-Viral Vector Manufacturing and Gene Therapy Manufacturing Market Report 2022 - ResearchAndMarkets.com - Business Wire - October 13th, 2022
- Exopharm identifies two new lead programs as exosomes gain prominence in gene therapy - Stockhead - October 13th, 2022
- What Do We Know About Gene Therapy and Cystic Fibrosis? - The Epoch Times - October 13th, 2022
- CSafe and BioLife Solutions, Inc. announce partnership to expand supply chain solutions for the cell and gene therapy market - PR Newswire APAC - PR... - October 13th, 2022
- Genomics in Cancer Care Market is estimated to be US$ 72.61 billion by 2032 with a CAGR of 16.3% during the forecast period 2032 - By PMI -... - October 13th, 2022
- After $100M deal, J&J links gene therapy to improved vision in early-phase trial - FierceBiotech - October 4th, 2022
- Bayer Head Admits COVID-19 Vaccine is Gene Therapy - October 4th, 2022
- New Gene Therapy Shows Promise for Treating Age Related Macular ... - October 4th, 2022
- BioMarin resubmits its hemophilia gene therapy to the FDA - BioPharma Dive - October 4th, 2022
- Why Philly ranks #2 among best cell and gene therapy hubs in the US - Technical.ly - October 4th, 2022
- AMPLIFYBIO ACQUIRES PACT PHARMA ASSETS TO ENHANCE CELL AND GENE THERAPY CHARACTERIZATION CAPABILITIES - PR Newswire - October 4th, 2022
- bluebird's (BLUE) Gene Therapy Approvals to Drive the Top Line - Zacks Investment Research - October 4th, 2022
- Researchers Develop Potential Gene Therapy to Treat Blindness - Managed Healthcare Executive - October 4th, 2022
- Voyager Therapeutics Announces Data Presentations at the 29th Annual Congress of the European Society of Gene & Cell Therapy - GlobeNewswire - October 4th, 2022
- Viral Vector Manufacturing, Non-Viral Vector Manufacturing and Gene Therapy Manufacturing Market by Scale of Operation, Type of Vector, Application... - October 4th, 2022
- Sanofi partners with Scribe to gain gene editing tools for cell therapy work - BioPharma Dive - October 4th, 2022
- Real Endpoints Marketplace announces collaboration with bluebird bio to help scale delivery of a first-of-its-kind value-based contract for one-time... - October 4th, 2022
- Vertex given green light to seek US approval of CRISPR-based therapy - BioPharma Dive - October 4th, 2022
- Atsena Therapeutics Announces Positive Results from Phase I/II Clinical Trial of ATSN-101 for the Treatment of GUCY2D-associated Leber Congenital... - October 4th, 2022
- Meet with the OrganaBio executives in-person at The Cell & Gene Meeting on the Mesa - Business Wire - October 4th, 2022
- Ocular Gene Therapy: A Literature Review With Focus on Current Clinical Trials - Cureus - September 25th, 2022
- Will experience support use of first-ever retinal gene therapy? - Ophthalmology Times - September 25th, 2022
- Rejuvenate Bio CEO highlights ambitious approach of using gene therapy to reverse aging - MedCity News - September 25th, 2022
- Gene therapy R&D market is projected to grow at a CAGR of 30.1% by 2032: Visiongain Reports Ltd - GlobeNewswire - September 25th, 2022
- Emulate Announces New Gene Therapy Application Enabling Accelerated Development of Treatments for Genetic Diseases with Organ-on-a-Chip Technology -... - September 25th, 2022
- CSL flexes gene therapy muscle with latest drug - Sydney Morning Herald - September 25th, 2022
- FDA Updates for the Week of Sept. 19, 2022 - Managed Healthcare Executive - September 25th, 2022
- AVROBIO Receives Rare Pediatric Disease Designation From FDA For First Gene Therapy In Development For Cy - Benzinga - September 25th, 2022
- Preparing Europe for a new generation of innovative therapies - Open Access Government - September 25th, 2022
- KSQ Therapeutics Announces Leadership and Board Additions - Business Wire - September 25th, 2022
- Hemophilia gene therapies from BioMarin, CSL pick up an early ICER endorsement - FiercePharma - September 16th, 2022
- Challenges In Gene Therapy - University of Utah - September 16th, 2022
- Hopkinton bioscience company forms advisory board for cell and gene therapy - Worcester Business Journal - September 16th, 2022
- Gene Therapy Restores Some Vision in Colorblind Children - Pharmacy Times - September 16th, 2022
- Coave Therapeutics partners with IMN on gene therapy - Labiotech.eu - September 16th, 2022
- MeiraGTx's Industry-Leading Gene Therapy Manufacturing Facility in Shannon, Ireland Formally Introduced by Head of Irish Government -... - September 16th, 2022
- Bluebird CFO resigns ahead of gene therapy launch - BioPharma Dive - September 16th, 2022
- Enrollment completed in STARLIGHT Phase 2 clinical trial of MCO-010 optogenetic gene therapy for Stargardt disease - Ophthalmology Times - September 16th, 2022
- Global Cancer Gene Therapy Market to Reach $11.35 Billion by 2030 at a CAGR of 23.3% - PR Newswire - September 16th, 2022
- How WhiteLab Genomics is using AI to aid gene and cell therapy development - TechCrunch - September 16th, 2022
- CAR-T Cell Therapy Market Segmentation and Forecast Analysis up to 2027 - BioSpace - September 16th, 2022
- Cluster-busters against Cancer and a Potential New Gene Therapy for LCA - BioSpace - September 16th, 2022
- Ori Biotech and CTMC team up on cell therapy delivery - BioPharma-Reporter.com - September 16th, 2022
- Adverum (ADVM) Doses First Patient in the Mid-Stage wAMD Study - Zacks Investment Research - September 16th, 2022
- Engensis Gene Therapy for ALS Found Safe in Small Phase 2a Trial |... - ALS News Today - September 8th, 2022
- A new gene therapy based on antibody cells is about to be tested in humans - MIT Technology Review - September 8th, 2022
- Myrtelles rAAV-Olig001-ASPA Gene Therapy Candidate for Canavan Disease Receives Advanced Therapy Medicinal Product Classification from the European... - September 8th, 2022
- Sangamo presses ahead with Fabry disease gene therapy - BioPharma Dive - September 8th, 2022
- The gene therapy that could transform the lives of millions - ABC News - September 8th, 2022
- As Philly becomes a hub for life sciences, a new program will train workers for jobs in the field - The Philadelphia Inquirer - September 8th, 2022
- Mayflower BioVentures to Announce New Cell & Gene Therapy Companies within Months - BioSpace - September 8th, 2022
- Carroucell Raises 1.5 Million to Introduce Breakthrough Microcarriers and Customizable Processes to Cell and Gene Therapy Market - Business Wire - September 8th, 2022